<code id='94615E2B53'></code><style id='94615E2B53'></style>
    • <acronym id='94615E2B53'></acronym>
      <center id='94615E2B53'><center id='94615E2B53'><tfoot id='94615E2B53'></tfoot></center><abbr id='94615E2B53'><dir id='94615E2B53'><tfoot id='94615E2B53'></tfoot><noframes id='94615E2B53'>

    • <optgroup id='94615E2B53'><strike id='94615E2B53'><sup id='94615E2B53'></sup></strike><code id='94615E2B53'></code></optgroup>
        1. <b id='94615E2B53'><label id='94615E2B53'><select id='94615E2B53'><dt id='94615E2B53'><span id='94615E2B53'></span></dt></select></label></b><u id='94615E2B53'></u>
          <i id='94615E2B53'><strike id='94615E2B53'><tt id='94615E2B53'><pre id='94615E2B53'></pre></tt></strike></i>

          Home / comprehensive / hotspot

          hotspot


          hotspot

          author:comprehensive    Page View:64
          Adam's take main illustration
          Molly Ferguson/STAT

          This week, a preview of the TUDCA study in ALS and thoughts on how it might impact Amylyx Pharmaceuticals. Also, I chatted with CRISPR Therapeutics CEO Sam Kulkarni about its new investor. Read to the end for some burning questions, random thoughts.

          The next ALS data readout — overdue but important

          A European academic consortium is expected to announce results soon from a clinical trial investigating the use of a widely available nutritional supplement called tauroursodeoxycholic acid, or TUDCA, in people living with ALS. The outcome of the TUDCA-ALS study could have implications for Amylyx Pharmaceuticals, because TUDCA is one of the two main ingredients in Relyvrio, the company’s approved drug for ALS.

          advertisement

          In a recent interview at Amylyx’s Kendall Square headquarters, co-CEOs Justin Klee and Josh Cohen mostly downplayed the suggestion that results from the randomized, placebo-controlled TUDCA study might affect Relyvrio negatively, or even positively.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In